Jim Cramer on Gilead's remdesivir study results and Regeneron

CNBC's Jim Cramer, Carl Quintanilla and David Faber discuss how investors should react to the latest headlines regarding the various treatments for coronavirus, including Gilead's positive results from it's study on remdesivir treatment for coronavirus.
Fri, Oct 9 20209:54 AM EDT